MCID: CLR014
MIFTS: 39

Clear Cell Adenoma

Categories: Cancer diseases

Aliases & Classifications for Clear Cell Adenoma

MalaCards integrated aliases for Clear Cell Adenoma:

Name: Clear Cell Adenoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5390
NCIt 50 C4151
SNOMED-CT 68 1752006
UMLS 73 C0334315

Summaries for Clear Cell Adenoma

Disease Ontology : 12 An adenoma that is composed_of cells with a clear cytoplasm located in ovary.

MalaCards based summary : Clear Cell Adenoma is related to parathyroid transitional clear cell adenoma and water-clear cell adenoma. An important gene associated with Clear Cell Adenoma is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Deactivation of the beta-catenin transactivating complex. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, ovary and lung, and related phenotypes are digestive/alimentary and craniofacial

Related Diseases for Clear Cell Adenoma

Diseases related to Clear Cell Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 parathyroid transitional clear cell adenoma 34.4 MEN1 PTH
2 water-clear cell adenoma 34.2 PTH TG
3 hyperparathyroidism 30.2 MEN1 PTH PTHLH
4 primary hyperparathyroidism 30.1 MEN1 PTH PTHLH
5 epithelial-myoepithelial carcinoma 11.2
6 extraskeletal chondroma 10.7 PTH PTHLH
7 sclerosing hepatic carcinoma 10.7 PTH PTHLH
8 invasive malignant thymoma 10.7 PTH PTHLH
9 hypocalciuric hypercalcemia, familial, type iii 10.6 PTH PTHLH
10 spondylosis 10.6 PTH S100B
11 oncogenic osteomalacia 10.6 PTH PTHLH
12 hypercalcemia, infantile, 1 10.6 PTH PTHLH
13 jaw cancer 10.6 PTH PTHLH
14 pseudohypoparathyroidism, type ib 10.5 PTH PTHLH
15 substernal goiter 10.5 PTH TG
16 postsurgical hypothyroidism 10.5 PTH TG
17 thyroid crisis 10.5 PTH TG
18 metaphyseal chondrodysplasia, jansen type 10.5 PTH PTHLH
19 functioning pituitary adenoma 10.5 MEN1 S100B
20 aggressive digital papillary adenocarcinoma 10.5 CEACAM5 S100B
21 duodenum cancer 10.4 MEN1 MUC2
22 microinvasive gastric cancer 10.4 CEACAM5 MUC2
23 immune system organ benign neoplasm 10.4 CEACAM5 PTH
24 nodular hidradenoma 10.4 CEACAM5 KITLG
25 thymus lipoma 10.4 CEACAM5 PTH
26 ectopic cushing syndrome 10.4 MEN1 S100B
27 breast adenomyoepithelioma 10.4 CEACAM5 KITLG
28 breast myoepithelial neoplasm 10.4 CEACAM5 KITLG
29 cervical clear cell adenocarcinoma 10.4 CEACAM5 KITLG
30 osteochondroma 10.4 PTHLH S100B
31 liver sarcoma 10.4 CEACAM5 PTHLH
32 hypoadrenalism 10.4 PTHLH TG
33 mineral metabolism disease 10.4 PTH PTHLH
34 multiple endocrine neoplasia, type iia 10.3 MEN1 PTH
35 clear cell acanthoma 10.3 CEACAM5 KITLG
36 adenoma 10.3
37 pseudohypoparathyroidism 10.3 PTH PTHLH
38 papillary adenocarcinoma 10.3 CEACAM5 MUC2
39 chondroid lipoma 10.3 CEACAM5 MEN1
40 islet cell tumor 10.3 MEN1 PTHLH
41 secretory meningioma 10.3 CEACAM5 MUC2
42 parathyroid carcinoma 10.3 MEN1 PTH
43 atypical follicular adenoma 10.3 CEACAM5 TG
44 juxtacortical chondroma 10.3 CTNNB1 PTHLH
45 acute thyroiditis 10.2 CEACAM5 TG
46 embryonal sarcoma 10.2 CTNNB1 S100B
47 periosteal chondrosarcoma 10.2 CTNNB1 PTHLH
48 polymorphous low-grade adenocarcinoma 10.2 CTNNB1 S100B
49 signet ring cell adenocarcinoma 10.2 CTNNB1 MUC2
50 spermatocele 10.2 CEACAM5 TG

Graphical network of the top 20 diseases related to Clear Cell Adenoma:



Diseases related to Clear Cell Adenoma

Symptoms & Phenotypes for Clear Cell Adenoma

MGI Mouse Phenotypes related to Clear Cell Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.73 MEN1 MUC2 MUC5AC PTHLH CTNNB1 KITLG
2 craniofacial MP:0005382 9.72 MEN1 PTH PTHLH CTNNB1 KITLG
3 endocrine/exocrine gland MP:0005379 9.7 MEN1 MUC2 PTH PTHLH CTNNB1 TG
4 homeostasis/metabolism MP:0005376 9.61 MUC2 MUC5AC PTH PTHLH CTNNB1 S100B
5 immune system MP:0005387 9.17 MEN1 MUC2 MUC5AC PTH PTHLH CTNNB1

Drugs & Therapeutics for Clear Cell Adenoma

Drugs for Clear Cell Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Doxil Approved June 1999 Phase 3,Phase 2 31703
7 Topoisomerase Inhibitors Phase 3,Phase 2
8 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
9 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
13
Sunitinib Approved, Investigational Phase 2,Not Applicable 341031-54-7, 557795-19-4 5329102
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
17
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
18
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
19
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
20
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
21
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
22
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
23
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
24
Nintedanib Approved Phase 2 656247-17-5 56843413
25
nivolumab Approved Phase 2 946414-94-4
26
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
27
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
30
Trebananib Investigational Phase 2 894356-79-7
31
Tremelimumab Investigational Phase 2 745013-59-6
32 Chelating Agents Phase 2
33 Angiogenesis Inhibitors Phase 2,Not Applicable
34 Angiogenesis Modulating Agents Phase 2,Not Applicable
35 Anticoagulants Phase 2
36 Calcium, Dietary Phase 2
37 Interleukin-2 Phase 2
38 Analgesics Phase 2
39 interferons Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Histone Deacetylase Inhibitors Phase 2
42 Peripheral Nervous System Agents Phase 2
43 Antibodies Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 2,Phase 1
46 Immunosuppressive Agents Phase 2,Phase 1
47 Anti-Infective Agents Phase 2,Phase 1
48 Interferon-alpha Phase 2
49 Antifungal Agents Phase 2,Phase 1
50 Anti-HIV Agents Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
5 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
6 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
9 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
10 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
11 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
12 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
13 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
14 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
15 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
16 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
17 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
18 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
19 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
20 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
21 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
22 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
23 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
24 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
25 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
26 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
27 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
28 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
29 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
30 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
31 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
32 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
33 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
34 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00563784 Phase 2 Erlotinib;Carboplatin;Paclitaxel
35 Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Not yet recruiting NCT03348631 Phase 2 Tazemetostat
36 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
37 ATN-161 in Advanced Renal Cell Cancer Terminated NCT00131651 Phase 2 ATN-161
38 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer Completed NCT00056537 Phase 1 ABR-217620
39 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
40 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Active, not recruiting NCT02837991 Phase 1 CDX-014
41 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting NCT01625351 Phase 1 alemtuzumab;fludarabine;sirolimus;Busulfan;melphalan
42 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
43 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036
44 Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy Completed NCT02282579 Pazopanib
45 The Role of Hypoxia as a Selective Pressure for TP53 Mutations Recruiting NCT03466034
46 Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting NCT01582204 Not Applicable 124IcG250
47 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Active, not recruiting NCT01504126 Not Applicable Propranolol;Chemotherapy
48 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395
49 Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Withdrawn NCT01732432

Search NIH Clinical Center for Clear Cell Adenoma

Genetic Tests for Clear Cell Adenoma

Anatomical Context for Clear Cell Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Clear Cell Adenoma:

19
Ovary

MalaCards organs/tissues related to Clear Cell Adenoma:

41
Ovary, Lung, Kidney, Lymph Node, Adrenal Gland, Thyroid

Publications for Clear Cell Adenoma

Articles related to Clear Cell Adenoma:

(show all 15)
# Title Authors Year
1
Water Clear Cell Adenoma of the Parathyroid Gland: A Forgotten Cause of Primary Hyperparathyroidism. ( 28382826 )
2017
2
Water-Clear Cell Adenoma of the Mediastinal Parathyroid Gland. ( 28832084 )
2017
3
Water-clear cell adenoma of parathyroid gland - A case report. ( 27772915 )
2016
4
Water-clear cell adenoma associated with primary hyperparathyroidism: report of a case. ( 23539328 )
2013
5
Water-clear cell adenoma: A rare form of hyperparathyroidism. ( 23995477 )
2013
6
A rare case of primary hyperparathyroidism with clear cell adenoma. ( 15118272 )
2004
7
Clear-cell adenoma of the fallopian tube, a rare tumor of the tubal mucosa. ( 15141314 )
2004
8
Water-clear cell adenoma of the parathyroid gland: a rare entity. ( 15471124 )
2004
9
Thyroid clear cell adenoma with marked dilatation of membranous structures: electron-microscopic study. ( 11758717 )
2001
10
Water-clear cell adenoma of the parathyroid. A case report with immunohistochemistry and electron microscopy. ( 7487410 )
1995
11
Large clear cell adenoma of the parathyroid in a patient with MEN-1 syndrome. Ultrastructural study of the tumour exhibiting unusual RER formations. ( 7725822 )
1994
12
Parotid clear-cell adenoma of possible myoepithelial origin. ( 5075358 )
1972
13
A comparative study of steroid biosyntheses in vitro. In clear cell adenoma and its adjacent tissue of human adrenal gland. ( 4241746 )
1969
14
A comparison of the conversion in vitro of pregnenolone sulphate and pregnenolone to steroid hormones by tissue from a clear cell adenoma of the adrenal gland. ( 5635101 )
1968
15
Corticosteroid synthesis in a clear cell adenoma: a time-based study. ( 4885809 )
1968

Variations for Clear Cell Adenoma

Expression for Clear Cell Adenoma

Search GEO for disease gene expression data for Clear Cell Adenoma.

Pathways for Clear Cell Adenoma

GO Terms for Clear Cell Adenoma

Cellular components related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 KITLG MUC5AC PTH PTHLH S100B TG
2 extracellular region GO:0005576 9.17 CEACAM5 KITLG MUC5AC PTH PTHLH S100B

Biological processes related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.76 CTNNB1 KITLG PTHLH S100B
2 regulation of gene expression GO:0010468 9.65 CTNNB1 PTH PTHLH
3 regulation of signaling receptor activity GO:0010469 9.62 KITLG PTH PTHLH TG
4 skeletal system development GO:0001501 9.58 CTNNB1 PTH PTHLH
5 beta-catenin-TCF complex assembly GO:1904837 9.49 CTNNB1 MEN1
6 bone resorption GO:0045453 9.43 CTNNB1 PTH
7 osteoblast development GO:0002076 9.37 MEN1 PTHLH
8 regulation of myelination GO:0031641 9.26 CTNNB1 TG
9 obsolete positive regulation of cAMP biosynthetic process GO:0030819 9.16 PTH PTHLH
10 cAMP metabolic process GO:0046058 8.96 PTH PTHLH
11 negative regulation of chondrocyte differentiation GO:0032331 8.8 CTNNB1 PTH PTHLH

Molecular functions related to Clear Cell Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 PTH PTHLH TG
2 peptide hormone receptor binding GO:0051428 8.62 PTH PTHLH

Sources for Clear Cell Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....